Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

NCT04598269 is registered in ClinicalTrials.gov with Aclaris Therapeutics, Inc. as lead sponsor.

NCT NCT04598269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04598269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Lead sponsor
Aclaris Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2020
Completion date
April 22, 2021
Enrollment
50 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis